USA VEBESEN BIOTECHNOLOGY LTD. – Trademark Portfolio

Entity Type: 03

USA VEBESEN BIOTECHNOLOGY LTD. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include VEYSS, LANIYO, SEFREAM, and VEBESEN. The owner is based in NEW YORK, NY.

228 PARK AVE S 30327

NEW YORK, NY 10003

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

VEBESEN
VEBESEN
Registered 2025
LANIYO
LANIYO
Registered 2025
VEYSS
VEYSS
Registered 2024
SEFREAM
SEFREAM
Registered 2020

Trademark Classifications

USA VEBESEN BIOTECHNOLOGY LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does USA VEBESEN BIOTECHNOLOGY LTD. have?

USA VEBESEN BIOTECHNOLOGY LTD. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does USA VEBESEN BIOTECHNOLOGY LTD. file in?

USA VEBESEN BIOTECHNOLOGY LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are USA VEBESEN BIOTECHNOLOGY LTD.'s most well-known trademarks?

USA VEBESEN BIOTECHNOLOGY LTD.'s registered trademark portfolio includes well-known marks such as VEYSS, LANIYO, SEFREAM, and VEBESEN. These are among 4 currently registered trademarks in the portfolio.

What is USA VEBESEN BIOTECHNOLOGY LTD.'s trademark registration success rate?

USA VEBESEN BIOTECHNOLOGY LTD. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.